董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Wendy Dixon | 女 | Director | 62 | 36.87万美元 | 未持股 | 2018-04-23 |
| Michael Higgins | 男 | Director | 55 | 14.99万美元 | 未持股 | 2018-04-23 |
| Steven Hyman | 男 | Director | 65 | 13.69万美元 | 未持股 | 2018-04-23 |
| Glenn F. Pierce | 男 | Director | 62 | 36.49万美元 | 未持股 | 2018-04-23 |
| Glenn Pierce | 男 | Director | 62 | 未披露 | 未持股 | 2018-04-23 |
| Steven M. Paul | 男 | Director, President and Chief Executive Officer | 67 | 265.54万美元 | 未持股 | 2018-04-23 |
| James Arthur Geraghty | 男 | Director | 63 | 14.26万美元 | 未持股 | 2018-04-23 |
| Perry Karsen | 男 | Director | 63 | 14.44万美元 | 未持股 | 2018-04-23 |
| Mark Levin | 男 | Director | 67 | 12.99万美元 | 未持股 | 2018-04-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dinah Sah | 女 | Chief Scientific Officer | 57 | 114.25万美元 | 未持股 | 2018-04-23 |
| Bernard Ravina | 男 | Chief Medical Officer | 51 | 47.48万美元 | 未持股 | 2018-04-23 |
| Matthew P. Ottmer | 男 | Chief Operating Officer | 47 | 282.94万美元 | 未持股 | 2018-04-23 |
| Jane Pritchett Henderson | 女 | Chief Financial Officer and Senior Vice President of Corporate Development | 52 | 未披露 | 未持股 | 2018-04-23 |
| Jane P. Henderson | 女 | Chief Financial Officer and Senior Vice President of Corporate Development | 52 | 224.67万美元 | 未持股 | 2018-04-23 |
| Steven M. Paul | 男 | Director, President and Chief Executive Officer | 67 | 265.54万美元 | 未持股 | 2018-04-23 |
董事简历
中英对照 | 中文 | 英文- Wendy Dixon
-
Wendy Dixon曾一直担任我们的董事会成员（2014年10月以来）。她一直担任Great Meadow Consulting公司（生命科学咨询公司）的总裁（2009年7月以来）。此外，她一直担任 the Mellon Group的顾问（2014年8月以来），也曾担任 The Monitor Group（现称为Deloitte Consulting LLP，咨询公司）的高级顾问（从2010年11月到2012年1月）。她也一直担任Longitude Capital公司（风险资本公司）的行业顾问委员会的成员（2015年3月以来）。从2001年到2009年，她曾担任Bristol-Myers Squibb公司的首席营销官和全球营销总裁，在那里她曾任职执行委员会。从1996年到2001年，她曾担任Merck and Co。的高级营销副总裁。此前，她曾担任West Pharmaceuticals公司、Osteotech公司、Centocor公司的执行管理职务，以及 SmithKline and French公司（现称为GlaxoSmithKline公司）的 市场营销、管理事务、项目管理职务和生物化学家。她任职于Alkermes公司、Incyte Corporation、bluebird bio公司、Orexigen Therapeutics公司的董事会，此前也曾任职于 Ardea Biosciences公司（基于Ardea公司被AstraZeneca公司收购）、Furiex Pharmaceuticals公司（基于Furiex公司被Actavis公司收购）、Dentsply International公司的董事会。她持有the University of Cambridge （英国）的自然科学学士和硕士学位，以及生物化学博士学位。
Wendy Dixon, Ph.D.,Dr. Dixon has been a member of the Board of Directors since January 2017. From 2010 to 2012 she was a senior advisor to The Monitor Group, now Monitor Deloitte, the global strategy consulting practice of Deloitte Consulting LLP. From 2001 to 2009 she served as Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb, where she served on the executive committee. From 1996 to 2001 she was Senior Vice President, Marketing at Merck & Co., a pharmaceutical company, with prior executive management positions at West Pharmaceuticals Services, Inc., Osteotech, Inc., and Centocor, Inc., and various positions at SmithKline & French Pharmaceuticals Co. now GlaxoSmithKline in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon has served on the boards of directors of publicly traded biopharmaceutical company Alkermes plc since January 2011 publicly traded biotechnology companies bluebird bio, Inc. since May 2013 and Eleven Biotherapeutics, Inc. since October 2014 and publicly traded pharmaceutical company Incyte Corporation since May 2010. She was formerly on the boards of directors of publicly traded companies Dentsply International, Inc., a dental company, from July 2005 to July 2010; Furiex Pharmaceuticals, Inc., a pharmaceutical company acquired by Actavis plc in 2014 from 2010 to 2014; Orexigen Therapeutics, Inc., a biopharmaceutical company, from April 2010 to January 2016; and Ardea Biosciences, Inc., a biopharmaceutical company acquired by AstraZeneca plc in 2012 from 2011 to 2012. Dr. Dixon received her B.Sc., M.Sc., and Ph.D. from the University of Cambridge (UK). - Wendy Dixon曾一直担任我们的董事会成员（2014年10月以来）。她一直担任Great Meadow Consulting公司（生命科学咨询公司）的总裁（2009年7月以来）。此外，她一直担任 the Mellon Group的顾问（2014年8月以来），也曾担任 The Monitor Group（现称为Deloitte Consulting LLP，咨询公司）的高级顾问（从2010年11月到2012年1月）。她也一直担任Longitude Capital公司（风险资本公司）的行业顾问委员会的成员（2015年3月以来）。从2001年到2009年，她曾担任Bristol-Myers Squibb公司的首席营销官和全球营销总裁，在那里她曾任职执行委员会。从1996年到2001年，她曾担任Merck and Co。的高级营销副总裁。此前，她曾担任West Pharmaceuticals公司、Osteotech公司、Centocor公司的执行管理职务，以及 SmithKline and French公司（现称为GlaxoSmithKline公司）的 市场营销、管理事务、项目管理职务和生物化学家。她任职于Alkermes公司、Incyte Corporation、bluebird bio公司、Orexigen Therapeutics公司的董事会，此前也曾任职于 Ardea Biosciences公司（基于Ardea公司被AstraZeneca公司收购）、Furiex Pharmaceuticals公司（基于Furiex公司被Actavis公司收购）、Dentsply International公司的董事会。她持有the University of Cambridge （英国）的自然科学学士和硕士学位，以及生物化学博士学位。
- Wendy Dixon, Ph.D.,Dr. Dixon has been a member of the Board of Directors since January 2017. From 2010 to 2012 she was a senior advisor to The Monitor Group, now Monitor Deloitte, the global strategy consulting practice of Deloitte Consulting LLP. From 2001 to 2009 she served as Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb, where she served on the executive committee. From 1996 to 2001 she was Senior Vice President, Marketing at Merck & Co., a pharmaceutical company, with prior executive management positions at West Pharmaceuticals Services, Inc., Osteotech, Inc., and Centocor, Inc., and various positions at SmithKline & French Pharmaceuticals Co. now GlaxoSmithKline in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon has served on the boards of directors of publicly traded biopharmaceutical company Alkermes plc since January 2011 publicly traded biotechnology companies bluebird bio, Inc. since May 2013 and Eleven Biotherapeutics, Inc. since October 2014 and publicly traded pharmaceutical company Incyte Corporation since May 2010. She was formerly on the boards of directors of publicly traded companies Dentsply International, Inc., a dental company, from July 2005 to July 2010; Furiex Pharmaceuticals, Inc., a pharmaceutical company acquired by Actavis plc in 2014 from 2010 to 2014; Orexigen Therapeutics, Inc., a biopharmaceutical company, from April 2010 to January 2016; and Ardea Biosciences, Inc., a biopharmaceutical company acquired by AstraZeneca plc in 2012 from 2011 to 2012. Dr. Dixon received her B.Sc., M.Sc., and Ph.D. from the University of Cambridge (UK).
- Michael Higgins
-
2015年7月以来Michael Higgins担任我们董事会的一员。2015年1月作为一名常驻企业家Higgins先生加入了Polaris的合作伙伴。加入Polaris 伙伴之前，Higgins先生担任Ironwood Pharmaceuticals公司的首席运营官和首席财务官。NASDAQ：IRWD从2003年到2014年12月。他在Ironwood工作之前，从1997年到2003年Higgins先生在Genzyme公司担任不同的领导职位包括副总裁、企业融资和副总裁、业务发展。在Genzyme期间，他参与多家企业包括细胞疗法、基因治疗、孤儿疾病业务单位。之前，从1992年到1997年Higgins先生担任Procept公司首席财务官。他也任职于 Genocea Biosciences公司Genocea和 .（纳斯达克：GNCA）和Pulmatrix公司董事会。在1986年作为Schering-Plough 公司的销售代表Higgins先生开始他的制药生涯。Higgins获得Cornell大学理学学士学位和，Dartmouth学院Amos Tuck 商学院的工商管理硕士学位。
Michael Higgins,Mr. Higgins has served as a member of the Board of Directors since July 2015. In January 2015 Mr. Higgins joined Polaris Partners as an entrepreneur in residence. Prior to joining Polaris Partners, Mr. Higgins served as Chief Operating Officer and Chief Financial Officer at Ironwood Pharmaceuticals, Inc. from May 2003 through December 2014. Prior to his work at Ironwood, from 1997 through 2003 Mr. Higgins worked at Genzyme Corporation in a variety of leadership roles including Vice President, Corporate Finance and Vice President, Business Development. While at Genzyme, he was involved with multiple businesses including the Cell Therapy, Gene Therapy, and Orphan Disease business units. Previously, Mr. Higgins served as Chief Financial Officer of Procept, Inc., from 1992 to 1997. He also has served on the boards of directors of publicly traded biotechnology companies Genocea Biosciences, Inc. since February 2015 and Pulmatrix, Inc. since May 2015 and privately held biotechnology companies KinDex Pharmaceuticals, Inc. since March 2016 Sea Pharmaceuticals LLC since January 2016 and Marauder Therapeutics, Inc. since October 2016 as well as Private Equity Access Fund, II. Mr. Higgins received his B.S. from Cornell University and holds an M.B.A. from the Amos Tuck School of Business at Dartmouth College. - 2015年7月以来Michael Higgins担任我们董事会的一员。2015年1月作为一名常驻企业家Higgins先生加入了Polaris的合作伙伴。加入Polaris 伙伴之前，Higgins先生担任Ironwood Pharmaceuticals公司的首席运营官和首席财务官。NASDAQ：IRWD从2003年到2014年12月。他在Ironwood工作之前，从1997年到2003年Higgins先生在Genzyme公司担任不同的领导职位包括副总裁、企业融资和副总裁、业务发展。在Genzyme期间，他参与多家企业包括细胞疗法、基因治疗、孤儿疾病业务单位。之前，从1992年到1997年Higgins先生担任Procept公司首席财务官。他也任职于 Genocea Biosciences公司Genocea和 .（纳斯达克：GNCA）和Pulmatrix公司董事会。在1986年作为Schering-Plough 公司的销售代表Higgins先生开始他的制药生涯。Higgins获得Cornell大学理学学士学位和，Dartmouth学院Amos Tuck 商学院的工商管理硕士学位。
- Michael Higgins,Mr. Higgins has served as a member of the Board of Directors since July 2015. In January 2015 Mr. Higgins joined Polaris Partners as an entrepreneur in residence. Prior to joining Polaris Partners, Mr. Higgins served as Chief Operating Officer and Chief Financial Officer at Ironwood Pharmaceuticals, Inc. from May 2003 through December 2014. Prior to his work at Ironwood, from 1997 through 2003 Mr. Higgins worked at Genzyme Corporation in a variety of leadership roles including Vice President, Corporate Finance and Vice President, Business Development. While at Genzyme, he was involved with multiple businesses including the Cell Therapy, Gene Therapy, and Orphan Disease business units. Previously, Mr. Higgins served as Chief Financial Officer of Procept, Inc., from 1992 to 1997. He also has served on the boards of directors of publicly traded biotechnology companies Genocea Biosciences, Inc. since February 2015 and Pulmatrix, Inc. since May 2015 and privately held biotechnology companies KinDex Pharmaceuticals, Inc. since March 2016 Sea Pharmaceuticals LLC since January 2016 and Marauder Therapeutics, Inc. since October 2016 as well as Private Equity Access Fund, II. Mr. Higgins received his B.S. from Cornell University and holds an M.B.A. from the Amos Tuck School of Business at Dartmouth College.
- Steven Hyman
-
Steven Hyman，自2015年9月成为董事会成员。他担任和哈佛大学和麻省理工学院布罗德研究所斯坦利精神病学研究中心（Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT）董事和布罗德研究所核心教师人员（2012年2月起）。Hyman先生自2011年7月起担任哈佛大学（Harvard University）干细胞和再生生物学著名服务教授。2001年12月-2011年6月他担任哈佛大学（Harvard University）教务长、大学首席学术官。1996-2001年他担任美国精神健康研究所（U.S. National Institute of Mental Health）的董事，专注投资神经科学和新兴基因技术。他于2000年被选如医学研究所（Institute of Medicine）并重命名国家医学院（National Academy of Medicine），目前在理事会、健康科学政策董事会工作，并担任神经科学和神经系统紊乱的董事。他是国际神经伦理学协会（International Neuroethics Society）的创立总裁、美洲艺术科学院（American Academy of Arts and Sciences）的研究员、美国科学发展协会（American Association for the Advancement of Science）研究员、美国神经精神药理学会（American College of Neuropsychopharmacology）的研究员和美国精神病学协会（American Psychiatric Association）著名生命研究员。他拥有耶鲁大学（Yale College）学士学位和剑桥大学（University of Cambridge）硕士学位，担任Mellon研究员，也拥有哈佛医学院（Harvard Medical School）硕士学位。
Steven Hyman, M.D.,Dr. Hyman has been a member of the Board of Directors since September 2015. He has served as director of the Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT and as a Core Faculty Member of the Broad Institute since February 2012. Dr. Hyman has served as a Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology since July 2011. From December 2001 to June 2011 he served as Provost of Harvard University, the University’s chief academic officer. From 1996 to 2001 he served as Director of the U.S. National Institute of Mental Health, where he emphasized investment in neuroscience and emerging genetic technologies. He also has served on the governing board of the National Research Council, the operating arm of the U.S. National Academies, since 2016. He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, a fellow and President-elect of the American College of Neuropsychopharmacology, and a Distinguished Life Fellow of the American Psychiatric Association. He has served on the board of directors of the privately held biotechnology company Q-State Biosciences, Inc. since January 2014. Dr. Hyman received a B.A. from Yale College, an M.A. from the University of Cambridge, which he attended as a Mellon fellow, and an M.D. from Harvard Medical School. - Steven Hyman，自2015年9月成为董事会成员。他担任和哈佛大学和麻省理工学院布罗德研究所斯坦利精神病学研究中心（Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT）董事和布罗德研究所核心教师人员（2012年2月起）。Hyman先生自2011年7月起担任哈佛大学（Harvard University）干细胞和再生生物学著名服务教授。2001年12月-2011年6月他担任哈佛大学（Harvard University）教务长、大学首席学术官。1996-2001年他担任美国精神健康研究所（U.S. National Institute of Mental Health）的董事，专注投资神经科学和新兴基因技术。他于2000年被选如医学研究所（Institute of Medicine）并重命名国家医学院（National Academy of Medicine），目前在理事会、健康科学政策董事会工作，并担任神经科学和神经系统紊乱的董事。他是国际神经伦理学协会（International Neuroethics Society）的创立总裁、美洲艺术科学院（American Academy of Arts and Sciences）的研究员、美国科学发展协会（American Association for the Advancement of Science）研究员、美国神经精神药理学会（American College of Neuropsychopharmacology）的研究员和美国精神病学协会（American Psychiatric Association）著名生命研究员。他拥有耶鲁大学（Yale College）学士学位和剑桥大学（University of Cambridge）硕士学位，担任Mellon研究员，也拥有哈佛医学院（Harvard Medical School）硕士学位。
- Steven Hyman, M.D.,Dr. Hyman has been a member of the Board of Directors since September 2015. He has served as director of the Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT and as a Core Faculty Member of the Broad Institute since February 2012. Dr. Hyman has served as a Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology since July 2011. From December 2001 to June 2011 he served as Provost of Harvard University, the University’s chief academic officer. From 1996 to 2001 he served as Director of the U.S. National Institute of Mental Health, where he emphasized investment in neuroscience and emerging genetic technologies. He also has served on the governing board of the National Research Council, the operating arm of the U.S. National Academies, since 2016. He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, a fellow and President-elect of the American College of Neuropsychopharmacology, and a Distinguished Life Fellow of the American Psychiatric Association. He has served on the board of directors of the privately held biotechnology company Q-State Biosciences, Inc. since January 2014. Dr. Hyman received a B.A. from Yale College, an M.A. from the University of Cambridge, which he attended as a Mellon fellow, and an M.D. from Harvard Medical School.
- Glenn F. Pierce
-
Glenn F. Pierce，2016年2月以来，他担任我们的董事会成员。他于2016年2月加入Third Rock Ventures公司（风险资本公司），并担任其驻企高管。2014年5月以来，他曾担任生物技术公司的研究和发展项目的独立顾问。他于2014年5月退任Biogen Inc.（生物技术公司），在那里他曾担任多种职务（2009年3月加入Biogen公司以来），包括血液学首席医疗官、全球医疗事务主管，最近领导血液、细胞和基因疗法部门。他拥有血友病和血红蛋白病的整体研发责任，并领导延长半衰期FVIII和修复Fc融合的研究和临床开发，于2014年最终促成多个监管机构的批准。他是150多篇科学论文的联席作者或合著者，并拥有15项以上的专利。他目前任职于the World Federation of Hemophilia WFH and WFHUSA的董事会、国家血友病基金会（NHF）（美国）医学和科学顾问委员会（the National Hemophilia Foundation （NHF） （U.S.） Medical and Scientific Advisory Council）。他持有 Case Western Reserve University（位于克利夫兰）的医学博士学位、免疫学博士学位，并在圣路易斯华盛顿大学（Washington University in St. Louis）进行病理学和血液学研究的研究生培训。
Glenn F. Pierce M.D., Ph.D. has served as a member of the company's Board of Directors since February 2016. In February 2016 Dr. Pierce joined Third Rock Ventures, a venture capital firm, as an independent consultant and entrepreneur-in-residence. He also serves on the World Federation of Hemophilia WFH and WFH USA Board of Directors and the National Hemophilia Foundation (NHF) (US) Medical and Scientific Advisory Council. Dr. Pierce is also a director of Voyager Therapeutics, a biopharmaceutical company. Dr. Pierce retired from Biogen in 2014 as senior vice president of Hematology, Cell and Gene Therapies. He had overall R&D responsibility for hemophilia and hemoglobinopathies and served as Chief Medical Officer since joining the company in 2009. Dr. Pierce was also responsible for global medical affairs for Biogen’s portfolio from 2012 to 2014. Dr. Pierce has 30 years’ experience in biotechnology research and development, is the co-author of more than 150 scientific papers and is a named inventor in over 15 patents. Dr. Pierce also served on the Blood Products Advisory Committee at the United States Food and Drug Administration and the Committee on Blood Safety and Availability at the United States Department of Health and Human Services. He received an M.D. and a Ph.D. in Immunology, both from Case Western Reserve University in Cleveland, Ohio and did his postgraduate training in pathology and hematology research at Washington University in St. Louis, Missouri. - Glenn F. Pierce，2016年2月以来，他担任我们的董事会成员。他于2016年2月加入Third Rock Ventures公司（风险资本公司），并担任其驻企高管。2014年5月以来，他曾担任生物技术公司的研究和发展项目的独立顾问。他于2014年5月退任Biogen Inc.（生物技术公司），在那里他曾担任多种职务（2009年3月加入Biogen公司以来），包括血液学首席医疗官、全球医疗事务主管，最近领导血液、细胞和基因疗法部门。他拥有血友病和血红蛋白病的整体研发责任，并领导延长半衰期FVIII和修复Fc融合的研究和临床开发，于2014年最终促成多个监管机构的批准。他是150多篇科学论文的联席作者或合著者，并拥有15项以上的专利。他目前任职于the World Federation of Hemophilia WFH and WFHUSA的董事会、国家血友病基金会（NHF）（美国）医学和科学顾问委员会（the National Hemophilia Foundation （NHF） （U.S.） Medical and Scientific Advisory Council）。他持有 Case Western Reserve University（位于克利夫兰）的医学博士学位、免疫学博士学位，并在圣路易斯华盛顿大学（Washington University in St. Louis）进行病理学和血液学研究的研究生培训。
- Glenn F. Pierce M.D., Ph.D. has served as a member of the company's Board of Directors since February 2016. In February 2016 Dr. Pierce joined Third Rock Ventures, a venture capital firm, as an independent consultant and entrepreneur-in-residence. He also serves on the World Federation of Hemophilia WFH and WFH USA Board of Directors and the National Hemophilia Foundation (NHF) (US) Medical and Scientific Advisory Council. Dr. Pierce is also a director of Voyager Therapeutics, a biopharmaceutical company. Dr. Pierce retired from Biogen in 2014 as senior vice president of Hematology, Cell and Gene Therapies. He had overall R&D responsibility for hemophilia and hemoglobinopathies and served as Chief Medical Officer since joining the company in 2009. Dr. Pierce was also responsible for global medical affairs for Biogen’s portfolio from 2012 to 2014. Dr. Pierce has 30 years’ experience in biotechnology research and development, is the co-author of more than 150 scientific papers and is a named inventor in over 15 patents. Dr. Pierce also served on the Blood Products Advisory Committee at the United States Food and Drug Administration and the Committee on Blood Safety and Availability at the United States Department of Health and Human Services. He received an M.D. and a Ph.D. in Immunology, both from Case Western Reserve University in Cleveland, Ohio and did his postgraduate training in pathology and hematology research at Washington University in St. Louis, Missouri.
- Glenn Pierce
-
Glenn Pierce，医学博士，博士，皮尔斯博士自2017年1月起担任董事会成员。他于2016年1月加入公司，并担任Third Rock Ventures，LLC的常驻企业家。他于2014年5月退任Biogen Idec公司（生物技术公司），在那里他曾任职（2009年3月以来），最近担任首席医疗官，领导血液学、细胞和基因疗法部门。在Biogen，Pierce博士牵头发起了与世界血友病联合会WFH和我的生活我们的未来的人道主义援助合作，这是一项全民基因型和基因组生物银行倡议。任职Biogen公司之前，他曾任职多种生物技术/生物制药公司，包括Bayer AG、Inspiration Pharma Ltd.、Avigen，Inc.、Selective Genetics，Inc.、Amgen，从事组织再生和血液学研究、开发，或两者兼而有之。Pierce博士是超过150篇科学论文的合著者，超过15项专利的作者，并为几种新颖的上市蛋白质的开发做出了贡献。他曾任职于医学和科学咨询委员会、董事会，也曾担任the National Hemophilia Foundation的董事会总裁（二十年）。Pierce博士还曾在美国食品和药物管理局（U.S.Food and Drug Administration）的血液制品咨询委员会和美国卫生与公共服务部（U.S.Department of Health and Human Services）的血液安全与可用性委员会任职。他自2015年起担任世界血友病联合会（英语:World Federation of Hemophilia）的董事会成员，并自2016年2月起担任上市生物制药公司全球血液疗法公司的董事。Pierce博士在克利夫兰的凯斯西储大学（Case Western Reserve University）获得生物学学士学位、医学博士学位和免疫学博士学位，并在圣路易斯的华盛顿大学（Washington University）完成了病理学和血液学研究的研究生培训。
Glenn Pierce, M.D., Ph.D.,Dr. Pierce has been a member of the Board of Directors since January 2017. He serves as entrepreneur-in-residence at Third Rock Ventures, LLC, having joined the company in January 2016. He retired from Biogen Idec, Inc., a biotechnology company, in May 2014 where he had worked since March 2009 and most recently served as Chief Medical Officer leading the Hematology, Cell and Gene Therapies division. At Biogen, Dr. Pierce spearheaded the initiation of the Humanitarian Aid Collaboration with the World Federation of Hemophilia WFH, and My Life Our Future, a population-wide genotyping and genomic biobank initiative. Prior to Biogen, he served in a variety of biotech/biopharma firms, including Bayer AG, Inspiration Pharma Ltd., Avigen, Inc., Selective Genetics, Inc., and Amgen, Inc. in the areas of tissue regeneration and hematology research, development, or both. Dr. Pierce is the co-author of more than 150 scientific papers, author of more than 15 patents, and has contributed to the development of several novel marketed proteins. He served on the Medical and Scientific Advisory Council, the board of directors and was president of the board of the National Hemophilia Foundation during a span of two decades. Dr. Pierce also served on the Blood Products Advisory Committee at the U.S. Food and Drug Administration and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. He has served on the board of directors of the World Federation of Hemophilia since 2015 and publicly traded biopharmaceutical company Global Blood Therapeutics, Inc. since February 2016. Dr. Pierce received a B.S. in Biology, an M.D., and a Ph.D. in immunology, all from Case Western Reserve University in Cleveland, and completed his postgraduate training in pathology and hematology research at Washington University in St. Louis. - Glenn Pierce，医学博士，博士，皮尔斯博士自2017年1月起担任董事会成员。他于2016年1月加入公司，并担任Third Rock Ventures，LLC的常驻企业家。他于2014年5月退任Biogen Idec公司（生物技术公司），在那里他曾任职（2009年3月以来），最近担任首席医疗官，领导血液学、细胞和基因疗法部门。在Biogen，Pierce博士牵头发起了与世界血友病联合会WFH和我的生活我们的未来的人道主义援助合作，这是一项全民基因型和基因组生物银行倡议。任职Biogen公司之前，他曾任职多种生物技术/生物制药公司，包括Bayer AG、Inspiration Pharma Ltd.、Avigen，Inc.、Selective Genetics，Inc.、Amgen，从事组织再生和血液学研究、开发，或两者兼而有之。Pierce博士是超过150篇科学论文的合著者，超过15项专利的作者，并为几种新颖的上市蛋白质的开发做出了贡献。他曾任职于医学和科学咨询委员会、董事会，也曾担任the National Hemophilia Foundation的董事会总裁（二十年）。Pierce博士还曾在美国食品和药物管理局（U.S.Food and Drug Administration）的血液制品咨询委员会和美国卫生与公共服务部（U.S.Department of Health and Human Services）的血液安全与可用性委员会任职。他自2015年起担任世界血友病联合会（英语:World Federation of Hemophilia）的董事会成员，并自2016年2月起担任上市生物制药公司全球血液疗法公司的董事。Pierce博士在克利夫兰的凯斯西储大学（Case Western Reserve University）获得生物学学士学位、医学博士学位和免疫学博士学位，并在圣路易斯的华盛顿大学（Washington University）完成了病理学和血液学研究的研究生培训。
- Glenn Pierce, M.D., Ph.D.,Dr. Pierce has been a member of the Board of Directors since January 2017. He serves as entrepreneur-in-residence at Third Rock Ventures, LLC, having joined the company in January 2016. He retired from Biogen Idec, Inc., a biotechnology company, in May 2014 where he had worked since March 2009 and most recently served as Chief Medical Officer leading the Hematology, Cell and Gene Therapies division. At Biogen, Dr. Pierce spearheaded the initiation of the Humanitarian Aid Collaboration with the World Federation of Hemophilia WFH, and My Life Our Future, a population-wide genotyping and genomic biobank initiative. Prior to Biogen, he served in a variety of biotech/biopharma firms, including Bayer AG, Inspiration Pharma Ltd., Avigen, Inc., Selective Genetics, Inc., and Amgen, Inc. in the areas of tissue regeneration and hematology research, development, or both. Dr. Pierce is the co-author of more than 150 scientific papers, author of more than 15 patents, and has contributed to the development of several novel marketed proteins. He served on the Medical and Scientific Advisory Council, the board of directors and was president of the board of the National Hemophilia Foundation during a span of two decades. Dr. Pierce also served on the Blood Products Advisory Committee at the U.S. Food and Drug Administration and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. He has served on the board of directors of the World Federation of Hemophilia since 2015 and publicly traded biopharmaceutical company Global Blood Therapeutics, Inc. since February 2016. Dr. Pierce received a B.S. in Biology, an M.D., and a Ph.D. in immunology, all from Case Western Reserve University in Cleveland, and completed his postgraduate training in pathology and hematology research at Washington University in St. Louis.
- Steven M. Paul
-
Steven M. Paul ，目前是阿佩尔阿尔茨海默氏症研究所主任，康奈尔大学威尔医学院神经病学，神经科学，精神病学和药理学教授。他有着超过20年的制药和生物技术行业的管理经验，及37多年的科研经验。他于2010年退休，时任美国礼来公司科学技术部执行副总裁，礼来研究实验室总裁，这是一个从事医药产品的研究，开发，制造销售的公司，他自2003年起担任该职。他于1993年加入礼来，此后在礼来公司的研究机构，担任了愈益重要的职务，其中包括探索研究与临床调查部副总裁。加入礼来之前，他曾在国家心理健康研究所担任多个高级职务，其中包括院内研究项目的科学顾问。他撰写或与他人合写了500余篇论文和特约书刊章节，并担任许多科学期刊的编委，及一些校外和校内委员会的授予校对人。他是Alnylam制药的董事，Third Rock Ventures的投资合伙人。他也是美国国家卫生研究院的董事，国家科学院医学研究所的成员，美国科学发展协会会员。他获得了杜兰大学医学博士，理科硕士和文科学士学位
Steven M. Paul, M.D.,Dr. Paul has served as our President, Chief Executive Officer, and member of the Board of Directors since September 2014. From June 2013 to September 2014 Dr. Paul served as our Interim President of Research and Development. Since September 2010 he has also served as a Venture Partner at Third Rock Ventures, LLC, a life sciences venture capital firm focused on the formation, development and strategy of new companies. Additionally, Dr. Paul has served as a professor or an adjunct professor of neuroscience at Weill Cornell Medical College since August 2010. Prior to that, from 1993 to 2010 Dr. Paul held several key positions at Eli Lilly and Company, a pharmaceutical company, including Executive Vice President, President of Lilly Research Laboratories, Vice President of Neuroscience CNS Research and Group Vice President of Discovery Research. Prior to Eli Lilly, from 1988 to 1993 Dr. Paul served as the Scientific Director of the National Institute of Mental Health. Dr. Paul also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Dr. Paul is an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine. He has also served on the boards of directors of publicly traded biopharmaceutical companies Alnylam Pharmaceuticals, Inc. since August 2010 and Sage Therapeutics, Inc. since September 2011. Dr. Paul has also served as a member of the Advisory Council of the National Institute of General Medical Sciences and was appointed by the Secretary of the Department of Health and Human Services as a member of the advisory committee to the Director of the National Institutes of Health, or NIH, from 2001 to 2005. He is currently the Chairman of the Foundation for the NIH board of directors. Dr. Paul is also board certified by the American Board of Psychiatry and Neurology. Dr. Paul received a B.A. in Biology and Psychology from Tulane University, and an M.S. and M.D. from the Tulane University School of Medicine. - Steven M. Paul ，目前是阿佩尔阿尔茨海默氏症研究所主任，康奈尔大学威尔医学院神经病学，神经科学，精神病学和药理学教授。他有着超过20年的制药和生物技术行业的管理经验，及37多年的科研经验。他于2010年退休，时任美国礼来公司科学技术部执行副总裁，礼来研究实验室总裁，这是一个从事医药产品的研究，开发，制造销售的公司，他自2003年起担任该职。他于1993年加入礼来，此后在礼来公司的研究机构，担任了愈益重要的职务，其中包括探索研究与临床调查部副总裁。加入礼来之前，他曾在国家心理健康研究所担任多个高级职务，其中包括院内研究项目的科学顾问。他撰写或与他人合写了500余篇论文和特约书刊章节，并担任许多科学期刊的编委，及一些校外和校内委员会的授予校对人。他是Alnylam制药的董事，Third Rock Ventures的投资合伙人。他也是美国国家卫生研究院的董事，国家科学院医学研究所的成员，美国科学发展协会会员。他获得了杜兰大学医学博士，理科硕士和文科学士学位
- Steven M. Paul, M.D.,Dr. Paul has served as our President, Chief Executive Officer, and member of the Board of Directors since September 2014. From June 2013 to September 2014 Dr. Paul served as our Interim President of Research and Development. Since September 2010 he has also served as a Venture Partner at Third Rock Ventures, LLC, a life sciences venture capital firm focused on the formation, development and strategy of new companies. Additionally, Dr. Paul has served as a professor or an adjunct professor of neuroscience at Weill Cornell Medical College since August 2010. Prior to that, from 1993 to 2010 Dr. Paul held several key positions at Eli Lilly and Company, a pharmaceutical company, including Executive Vice President, President of Lilly Research Laboratories, Vice President of Neuroscience CNS Research and Group Vice President of Discovery Research. Prior to Eli Lilly, from 1988 to 1993 Dr. Paul served as the Scientific Director of the National Institute of Mental Health. Dr. Paul also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Dr. Paul is an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine. He has also served on the boards of directors of publicly traded biopharmaceutical companies Alnylam Pharmaceuticals, Inc. since August 2010 and Sage Therapeutics, Inc. since September 2011. Dr. Paul has also served as a member of the Advisory Council of the National Institute of General Medical Sciences and was appointed by the Secretary of the Department of Health and Human Services as a member of the advisory committee to the Director of the National Institutes of Health, or NIH, from 2001 to 2005. He is currently the Chairman of the Foundation for the NIH board of directors. Dr. Paul is also board certified by the American Board of Psychiatry and Neurology. Dr. Paul received a B.A. in Biology and Psychology from Tulane University, and an M.S. and M.D. from the Tulane University School of Medicine.
- James Arthur Geraghty
-
James Arthur Geraghty先生，于2018年7月18日获委任为北海康成制药有限公司独立非执行董事。Geraghty先生自2017年5月起担任公司的全资附属公司北海康成医药科技的独立非执行董事。Geraghty先生负责监督董事会并为董事会提供独立判断。Geraghty先生在业务发展、战略及营运方面拥有约30年管理经验。于2013年5月至2016年12月，Geraghty先生为Third Rock Ventures的驻场企业家，负责公司组建及治理。在此之前，Geraghty先生于2011年4月至2012年12月期间担任Sanofi S.A.的高级副总裁，负责战略及业务发展。Geraghty先生于1992年至2011年任职于美国健赞公司，其在此担任的最后职位是负责国际开发的高级副总裁。于1993年至2007年，Geraghty先生担任Genzyme Transgenics Corporation的董事会主席及首席执行官。此前，Geraghty先生在贝恩资本开启职业生涯，负责医疗健康策略咨询。Geraghty先生自2018年5月及2017年11月起分别担任Orchard Therapeutics（纳斯达克：ORTX）及Pieris Pharmaceuticals（纳斯达克：PIRS）的董事会主席。Geraghty先生亦自2016年10月、2014年1月及2013年7月起分别担任Fulcrum Therapeutics（纳斯达克：PIRS）、Voyager Therapeutics（纳斯达克：VYGR）及Idera Pharmaceuticals（纳斯达克：IDRA）的独立非雇员董事。Geraghty先生于1980年5月在乔治敦大学获得心理学学士学位及在耶鲁大学法学院获得法学博士学位。
James Arthur Geraghty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2013 and as chair of Idera Pharmaceuticals, Inc. Board of Directors from that time until 2021. Mr. Geraghty is an industry leader with over 35 years of strategic and leadership experience, including more than 25 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From 2013 to 2016, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund. From 2011 to 2012, he served as a Senior Vice President of Sanofi S.A., a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to 2011, including as Senior Vice President of International Development and President of Genzyme Europe. Mr. Geraghty currently serves as chairman of the board of Orchard Therapeutics plc and Pieris Pharmaceuticals, Inc. and as a member of the board of Voyager Therapeutics, Inc., and Fulcrum Therapeutics, Inc. He also previously served as a director of bluebird bio, Inc. and GTC Biotherapeutics, Inc. - James Arthur Geraghty先生，于2018年7月18日获委任为北海康成制药有限公司独立非执行董事。Geraghty先生自2017年5月起担任公司的全资附属公司北海康成医药科技的独立非执行董事。Geraghty先生负责监督董事会并为董事会提供独立判断。Geraghty先生在业务发展、战略及营运方面拥有约30年管理经验。于2013年5月至2016年12月，Geraghty先生为Third Rock Ventures的驻场企业家，负责公司组建及治理。在此之前，Geraghty先生于2011年4月至2012年12月期间担任Sanofi S.A.的高级副总裁，负责战略及业务发展。Geraghty先生于1992年至2011年任职于美国健赞公司，其在此担任的最后职位是负责国际开发的高级副总裁。于1993年至2007年，Geraghty先生担任Genzyme Transgenics Corporation的董事会主席及首席执行官。此前，Geraghty先生在贝恩资本开启职业生涯，负责医疗健康策略咨询。Geraghty先生自2018年5月及2017年11月起分别担任Orchard Therapeutics（纳斯达克：ORTX）及Pieris Pharmaceuticals（纳斯达克：PIRS）的董事会主席。Geraghty先生亦自2016年10月、2014年1月及2013年7月起分别担任Fulcrum Therapeutics（纳斯达克：PIRS）、Voyager Therapeutics（纳斯达克：VYGR）及Idera Pharmaceuticals（纳斯达克：IDRA）的独立非雇员董事。Geraghty先生于1980年5月在乔治敦大学获得心理学学士学位及在耶鲁大学法学院获得法学博士学位。
- James Arthur Geraghty has served on Idera Pharmaceuticals, Inc. Board of Directors since 2013 and as chair of Idera Pharmaceuticals, Inc. Board of Directors from that time until 2021. Mr. Geraghty is an industry leader with over 35 years of strategic and leadership experience, including more than 25 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From 2013 to 2016, Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund. From 2011 to 2012, he served as a Senior Vice President of Sanofi S.A., a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to 2011, including as Senior Vice President of International Development and President of Genzyme Europe. Mr. Geraghty currently serves as chairman of the board of Orchard Therapeutics plc and Pieris Pharmaceuticals, Inc. and as a member of the board of Voyager Therapeutics, Inc., and Fulcrum Therapeutics, Inc. He also previously served as a director of bluebird bio, Inc. and GTC Biotherapeutics, Inc.
- Perry Karsen
-
Perry Karsen，自2020年10月起担任Graphite Bio, Inc.董事会主席，自2020年6月起担任Graphite Bio, Inc.董事会成员。从2013年5月到2015年12月，他担任Celgene Cellular Therapeutics, Inc. （Celgene Corporation的一个部门，统称为“Celgene”）的首席执行官。在此之前，他从2010年7月到2013年5月担任Celgene的首席运营官和执行副总裁，从2004年到2009年担任Celgene的高级副总裁和全球业务发展主管。从2009年2月到2010年7月，Karsen先生担任Pearl Therapeutics Inc.（随后被AstraZeneca plc收购）的首席执行官。（纳斯达克：下跌）。在此之前，Karsen先生曾担任Human Genome Sciences, Inc.（上市的生物技术公司，自被GlaxoSmithKline plc (Swiss： GSK.SW）收购）、Bristol-Myers Squibb Co.、Genentech, Inc.（自被Hoffmann-La Roche AG (Roche）收购）和Abbott Laboratories的高管职位。此外，他曾担任Pequot Capital Management, Inc.的普通合伙人。他目前是Jounce Therapeutics, Inc.（纳斯达克股票代码：JNCE）的董事会成员（2016年1月以来）和Nitrase Therapeutics, Inc.（2020年5月以来）的董事会成员。Karsen先生曾担任多家上市生物技术公司的董事会成员，包括2016年4月至2020年12月Intellia Therapeutics, Inc.（纳斯达克股票代码：INTL）， 2016年1月至2019年4月Oncomed Pharmaceuticals, Inc.（纳斯达克股票代码：OMED）（直到被Mereo BioPharma（纳斯达克股票代码：MREO）收购），2015年7月至2019年8月Voyager Therapeutics, Inc.（纳斯达克股票代码：VYGR）， Agios Pharmaceuticals, Inc.（纳斯达克股票代码：AGIO） 2011年11月至2016年3月和Alliqua Biomedical, Inc.（纳斯达克股票代码：MREO）。从2013年12月到2016年2月。他还曾担任the Biotechnology Innovation Organization （BIO）和the Alliance for Regenerative Medicine的董事会成员。他持有University of Illinois, Urbana-Champaign生物科学学士学位、Northwestern University's Kellogg Graduate School管理硕士学位和Duke University生物学硕士学位。
Perry Karsen,has served as the chair of Graphite Bio, Inc. board of directors since October 2020 and as a member of Graphite Bio, Inc. board of directors since June 2020. From May 2013 to December 2015, Mr. Karsen was the Chief Executive Officer of Celgene Cellular Therapeutics, Inc., a division of Celgene Corporation (collectively, "Celgene"). Prior to that, Mr. Karsen served as Chief Operations Officer and Executive Vice President of Celgene from July 2010 to May 2013 and as Senior Vice President and Head of Worldwide Business Development of Celgene from 2004 to 2009. From February 2009 and July 2010, Mr. Karsen was Chief Executive Officer of Pearl Therapeutics Inc., subsequently acquired by AstraZeneca plc. (NASDAQ: AZN). Prior to that, Mr. Karsen held executive positions at Human Genome Sciences, Inc., a publicly traded biotechnology company (since acquired by GlaxoSmithKline plc (Swiss: GSK.SW)), Bristol-Myers Squibb Co., Genentech, Inc. (since acquired by Hoffmann-La Roche AG (Roche)), and Abbott Laboratories. In addition, Mr. Karsen served as a General Partner at Pequot Capital Management, Inc. He is currently a member of the boards of Jounce Therapeutics, Inc. (NASDAQ: JNCE) since January 2016 and Nitrase Therapeutics, Inc. since May 2020. Mr. Karsen formerly served on the boards of several public biotechnology companies, including Intellia Therapeutics, Inc. (NASDAQ: INTL) from April 2016 to December 2020, Oncomed Pharmaceuticals, Inc. (NASDAQ: OMED) (until it was acquired by Mereo BioPharma (NASDAQ: MREO)), from January 2016 to April 2019, Voyager Therapeutics, Inc. (NASDAQ: VYGR) from July 2015 to August 2019, Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) from November 2011 to March 2016, and Alliqua Biomedical, Inc. (NASDAQ: ALQA) from December 2013 to February 2016. Mr. Karsen was also formerly a member of the boards of directors of the Biotechnology Innovation Organization (BIO) and the Alliance for Regenerative Medicine. Mr. Karsen received his B.S. in Biological Sciences from the University of Illinois, Urbana-Champaign, a Masters of Management from Northwestern University's Kellogg Graduate School of Management and an M.A.T. in Biology from Duke University. - Perry Karsen，自2020年10月起担任Graphite Bio, Inc.董事会主席，自2020年6月起担任Graphite Bio, Inc.董事会成员。从2013年5月到2015年12月，他担任Celgene Cellular Therapeutics, Inc. （Celgene Corporation的一个部门，统称为“Celgene”）的首席执行官。在此之前，他从2010年7月到2013年5月担任Celgene的首席运营官和执行副总裁，从2004年到2009年担任Celgene的高级副总裁和全球业务发展主管。从2009年2月到2010年7月，Karsen先生担任Pearl Therapeutics Inc.（随后被AstraZeneca plc收购）的首席执行官。（纳斯达克：下跌）。在此之前，Karsen先生曾担任Human Genome Sciences, Inc.（上市的生物技术公司，自被GlaxoSmithKline plc (Swiss： GSK.SW）收购）、Bristol-Myers Squibb Co.、Genentech, Inc.（自被Hoffmann-La Roche AG (Roche）收购）和Abbott Laboratories的高管职位。此外，他曾担任Pequot Capital Management, Inc.的普通合伙人。他目前是Jounce Therapeutics, Inc.（纳斯达克股票代码：JNCE）的董事会成员（2016年1月以来）和Nitrase Therapeutics, Inc.（2020年5月以来）的董事会成员。Karsen先生曾担任多家上市生物技术公司的董事会成员，包括2016年4月至2020年12月Intellia Therapeutics, Inc.（纳斯达克股票代码：INTL）， 2016年1月至2019年4月Oncomed Pharmaceuticals, Inc.（纳斯达克股票代码：OMED）（直到被Mereo BioPharma（纳斯达克股票代码：MREO）收购），2015年7月至2019年8月Voyager Therapeutics, Inc.（纳斯达克股票代码：VYGR）， Agios Pharmaceuticals, Inc.（纳斯达克股票代码：AGIO） 2011年11月至2016年3月和Alliqua Biomedical, Inc.（纳斯达克股票代码：MREO）。从2013年12月到2016年2月。他还曾担任the Biotechnology Innovation Organization （BIO）和the Alliance for Regenerative Medicine的董事会成员。他持有University of Illinois, Urbana-Champaign生物科学学士学位、Northwestern University's Kellogg Graduate School管理硕士学位和Duke University生物学硕士学位。
- Perry Karsen,has served as the chair of Graphite Bio, Inc. board of directors since October 2020 and as a member of Graphite Bio, Inc. board of directors since June 2020. From May 2013 to December 2015, Mr. Karsen was the Chief Executive Officer of Celgene Cellular Therapeutics, Inc., a division of Celgene Corporation (collectively, "Celgene"). Prior to that, Mr. Karsen served as Chief Operations Officer and Executive Vice President of Celgene from July 2010 to May 2013 and as Senior Vice President and Head of Worldwide Business Development of Celgene from 2004 to 2009. From February 2009 and July 2010, Mr. Karsen was Chief Executive Officer of Pearl Therapeutics Inc., subsequently acquired by AstraZeneca plc. (NASDAQ: AZN). Prior to that, Mr. Karsen held executive positions at Human Genome Sciences, Inc., a publicly traded biotechnology company (since acquired by GlaxoSmithKline plc (Swiss: GSK.SW)), Bristol-Myers Squibb Co., Genentech, Inc. (since acquired by Hoffmann-La Roche AG (Roche)), and Abbott Laboratories. In addition, Mr. Karsen served as a General Partner at Pequot Capital Management, Inc. He is currently a member of the boards of Jounce Therapeutics, Inc. (NASDAQ: JNCE) since January 2016 and Nitrase Therapeutics, Inc. since May 2020. Mr. Karsen formerly served on the boards of several public biotechnology companies, including Intellia Therapeutics, Inc. (NASDAQ: INTL) from April 2016 to December 2020, Oncomed Pharmaceuticals, Inc. (NASDAQ: OMED) (until it was acquired by Mereo BioPharma (NASDAQ: MREO)), from January 2016 to April 2019, Voyager Therapeutics, Inc. (NASDAQ: VYGR) from July 2015 to August 2019, Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) from November 2011 to March 2016, and Alliqua Biomedical, Inc. (NASDAQ: ALQA) from December 2013 to February 2016. Mr. Karsen was also formerly a member of the boards of directors of the Biotechnology Innovation Organization (BIO) and the Alliance for Regenerative Medicine. Mr. Karsen received his B.S. in Biological Sciences from the University of Illinois, Urbana-Champaign, a Masters of Management from Northwestern University's Kellogg Graduate School of Management and an M.A.T. in Biology from Duke University.
- Mark Levin
-
Mark Levin，自2010年以来认我们的董事会成员。他目前是Third Rock Ventures的合伙人，该公司是一个生命科学风险资本公司，集中在新公司的形成、发展和战略。他在2007年合伙创建了这一基金会。从1993年到2005年，他担任 Millennium Pharmaceuticals公司的创立首席执行官。他是一家全球风险投资公司 Mayfield Fund的生命科学创始人，在那里他从1989年到1991年也是 Cell Genesys公司的创立首席执行官；从1991年到1992年任Tularik公司的首席执行官；从1992年到1993年任Focal公司的首席执行官；从1990年到1992年任StemCells 公司（纳斯达克：STEM）的首席执行官。他开始他的职业生涯是作为Eli Lilly and Company（纳斯达克：LLY）和Genentech公司的工程师及项目负责人。他持有华盛顿大学化学和生物医学工程学士和硕士。
Mark Levin has served as a member of our board of directors since August 2015 and chairman of our board of directors since August 2016. Mr. Levin currently serves as a partner at Third Rock Ventures, LLC, which he co-founded in 2007. Mr. Levin served as our interim president and chief executive officer from August 2015 to July 2016 and as interim president and chief executive officer of Voyager Therapeutics, Inc., or Voyager, a biotechnology company, from June 2013 to September 2014. He has served as the chairman of the board of directors of Voyager since June 2013. Mr. Levin was formerly on the boards of publicly traded life sciences companies Eleven Biotherapeutics, Inc. from September 2008 to November 2014 and Foundation Medicine, Inc. from 2010 to June 2014. Mr. Levin served as founding chief executive officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited, from 1993 to 2005. Mr. Levin received both a B.S. and an M.S. in Chemical and Biochemical Engineering from Washington University in St. Louis. - Mark Levin，自2010年以来认我们的董事会成员。他目前是Third Rock Ventures的合伙人，该公司是一个生命科学风险资本公司，集中在新公司的形成、发展和战略。他在2007年合伙创建了这一基金会。从1993年到2005年，他担任 Millennium Pharmaceuticals公司的创立首席执行官。他是一家全球风险投资公司 Mayfield Fund的生命科学创始人，在那里他从1989年到1991年也是 Cell Genesys公司的创立首席执行官；从1991年到1992年任Tularik公司的首席执行官；从1992年到1993年任Focal公司的首席执行官；从1990年到1992年任StemCells 公司（纳斯达克：STEM）的首席执行官。他开始他的职业生涯是作为Eli Lilly and Company（纳斯达克：LLY）和Genentech公司的工程师及项目负责人。他持有华盛顿大学化学和生物医学工程学士和硕士。
- Mark Levin has served as a member of our board of directors since August 2015 and chairman of our board of directors since August 2016. Mr. Levin currently serves as a partner at Third Rock Ventures, LLC, which he co-founded in 2007. Mr. Levin served as our interim president and chief executive officer from August 2015 to July 2016 and as interim president and chief executive officer of Voyager Therapeutics, Inc., or Voyager, a biotechnology company, from June 2013 to September 2014. He has served as the chairman of the board of directors of Voyager since June 2013. Mr. Levin was formerly on the boards of publicly traded life sciences companies Eleven Biotherapeutics, Inc. from September 2008 to November 2014 and Foundation Medicine, Inc. from 2010 to June 2014. Mr. Levin served as founding chief executive officer of Millennium Pharmaceuticals, Inc., a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited, from 1993 to 2005. Mr. Levin received both a B.S. and an M.S. in Chemical and Biochemical Engineering from Washington University in St. Louis.
高管简历
中英对照 | 中文 | 英文- Dinah Sah
Dinah Sah，自2014年3月起担任神经科学高级副总裁。在加入公司之前，Sah先生担任生物技术研发顾问（2012年2月-2014年3月）。在这之前，Sah先生在Alnylam Pharmaceuticals股份有限公司（Alnylam Pharmaceuticals, Inc.，NASDAQ： ALNY）担任几个职位，包括研究副总裁（2010-2012年）；中枢神经系统和肿瘤研究副总裁（2008-2010年）；担任研究高级董事（2005-2008年）。1999-2005年她在Biogen Idec股份有限公司（Biogen Idec, Inc.， （NASDAQ： BIIB））工作，目前担任神经科学助理董事和负责人。在那之前，他在Signal Pharmaceuticals担任神经科学助理董事（1997-1999年）。她拥有麻省理工学院（Massachusetts Institute of Technology）生物学士学位；哈佛大学（Harvard University）神经科学博士学位，还完成了她在哈佛大学（Harvard University）神经生物的研究生培训。
Dinah Sah, Ph.D.,Dr. Sah has served as our Chief Scientific Officer since January 2017 and was previously our Senior Vice President of Neuroscience beginning in March 2014. Prior to joining us, Dr. Sah served as a biotechnology research and development consultant from February 2012 to March 2014. Previously, Dr. Sah held several positions at Alnylam Pharmaceuticals, Inc. including Vice President of Research from 2010 to 2012 Vice President of Research, CNS and Oncology from 2008 to 2010 and Senior Director of Research from 2005 to 2008. From 1999 to 2005 she worked at Biogen, most recently as Associate Director & Head of Neurobiology. Prior to that, Dr. Sah served as the Associate Director of Neurobiology at Signal Pharmaceuticals from 1997 to 1999. Dr. Sah received a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Neurobiology from Harvard University, and completed her post‑doctoral training at Harvard University’s Department of Neurobiology.- Dinah Sah，自2014年3月起担任神经科学高级副总裁。在加入公司之前，Sah先生担任生物技术研发顾问（2012年2月-2014年3月）。在这之前，Sah先生在Alnylam Pharmaceuticals股份有限公司（Alnylam Pharmaceuticals, Inc.，NASDAQ： ALNY）担任几个职位，包括研究副总裁（2010-2012年）；中枢神经系统和肿瘤研究副总裁（2008-2010年）；担任研究高级董事（2005-2008年）。1999-2005年她在Biogen Idec股份有限公司（Biogen Idec, Inc.， （NASDAQ： BIIB））工作，目前担任神经科学助理董事和负责人。在那之前，他在Signal Pharmaceuticals担任神经科学助理董事（1997-1999年）。她拥有麻省理工学院（Massachusetts Institute of Technology）生物学士学位；哈佛大学（Harvard University）神经科学博士学位，还完成了她在哈佛大学（Harvard University）神经生物的研究生培训。
- Dinah Sah, Ph.D.,Dr. Sah has served as our Chief Scientific Officer since January 2017 and was previously our Senior Vice President of Neuroscience beginning in March 2014. Prior to joining us, Dr. Sah served as a biotechnology research and development consultant from February 2012 to March 2014. Previously, Dr. Sah held several positions at Alnylam Pharmaceuticals, Inc. including Vice President of Research from 2010 to 2012 Vice President of Research, CNS and Oncology from 2008 to 2010 and Senior Director of Research from 2005 to 2008. From 1999 to 2005 she worked at Biogen, most recently as Associate Director & Head of Neurobiology. Prior to that, Dr. Sah served as the Associate Director of Neurobiology at Signal Pharmaceuticals from 1997 to 1999. Dr. Sah received a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Neurobiology from Harvard University, and completed her post‑doctoral training at Harvard University’s Department of Neurobiology.
- Bernard Ravina
Bernard Ravina，自2014年3月起担任临床发展副总裁。在加入公司之前，Ravina博士是Biogen Idec NASDAQ： BIIB的临床发展医学董事（2010年10月-2014年3月），他曾用小分子药物和生物制剂治疗神经系统疾病，负责帕金森疾病（Parkinson's disease）、中风和神经性疼痛的生物标志物和临床开发计划。在那之前，他是神经内科助理教授、运动和遗传性神经系统疾病的董事和罗切斯特大学医学院（Rochester School of Medicine）神经内科助理主任（2005年8月-2010年10月）。Ravina先生拥有Johns Hopkins大学医学院（Johns Hopkins University School of Medicine）硕士学位和宾夕法尼亚大学（University of Pennsylvania）临床流行病学和生物统计学硕士学位。他完成了宾夕法尼亚大学（University of Pennsylvania）帕金森病与运动障碍的研究和神经内科住院医师培训。
Bernard Ravina has served as our Chief Medical Officer since August 2018. Prior to joining us, Dr. Ravina was at Voyager Therapeutics, Inc. NASDAQ: VYGR, where he served as Chief Medical Officer from February 2017 to August 2018 and as Vice President of Clinical Development from March 2014 to January 2017. Dr. Ravina was also Medical Director in Clinical Development at Biogen Inc. (NASDAQ: BIIB), or Biogen, from 2010 to 2014 where he worked on both small molecule drugs and biologics for the treatment of neurological disorders. From 2005 to 2010 Dr. Ravina was an Associate Professor of Neurology, Director of the Movement and Inherited Neurological Disorders Unit, Associate Director of Clinical Trials Coordination Center and Vice Chair of Neurology at the University of Rochester School of Medicine. Dr. Ravina received a B.A. in psychology from Columbia University, an M.D. from Johns Hopkins University School of Medicine and an M.S.C.E. in clinical epidemiology from the University of Pennsylvania where he completed his residency and fellowship training in Neurology.- Bernard Ravina，自2014年3月起担任临床发展副总裁。在加入公司之前，Ravina博士是Biogen Idec NASDAQ： BIIB的临床发展医学董事（2010年10月-2014年3月），他曾用小分子药物和生物制剂治疗神经系统疾病，负责帕金森疾病（Parkinson's disease）、中风和神经性疼痛的生物标志物和临床开发计划。在那之前，他是神经内科助理教授、运动和遗传性神经系统疾病的董事和罗切斯特大学医学院（Rochester School of Medicine）神经内科助理主任（2005年8月-2010年10月）。Ravina先生拥有Johns Hopkins大学医学院（Johns Hopkins University School of Medicine）硕士学位和宾夕法尼亚大学（University of Pennsylvania）临床流行病学和生物统计学硕士学位。他完成了宾夕法尼亚大学（University of Pennsylvania）帕金森病与运动障碍的研究和神经内科住院医师培训。
- Bernard Ravina has served as our Chief Medical Officer since August 2018. Prior to joining us, Dr. Ravina was at Voyager Therapeutics, Inc. NASDAQ: VYGR, where he served as Chief Medical Officer from February 2017 to August 2018 and as Vice President of Clinical Development from March 2014 to January 2017. Dr. Ravina was also Medical Director in Clinical Development at Biogen Inc. (NASDAQ: BIIB), or Biogen, from 2010 to 2014 where he worked on both small molecule drugs and biologics for the treatment of neurological disorders. From 2005 to 2010 Dr. Ravina was an Associate Professor of Neurology, Director of the Movement and Inherited Neurological Disorders Unit, Associate Director of Clinical Trials Coordination Center and Vice Chair of Neurology at the University of Rochester School of Medicine. Dr. Ravina received a B.A. in psychology from Columbia University, an M.D. from Johns Hopkins University School of Medicine and an M.S.C.E. in clinical epidemiology from the University of Pennsylvania where he completed his residency and fellowship training in Neurology.
- Matthew P. Ottmer
Matthew P. Ottmer，2015年12月以来，他一直是我们的首席运营官。他曾担任Biogen, Inc.（生物技术公司）的高级副总裁，负责策略和新兴企业（2014年7月至2015年7月）。此前，他曾担任Biogen公司的那他珠单抗（Tysabri）业务负责人（2012年3月至2014年7月），也曾担任Biogen公司的首席执行官的首席职员（2010年10月至2012年3月）。他于1999年加入Biogen公司。他持有the University of Michigan的政治科学学士学位，以及西北大学凯洛格管理学院（Northwestern University's Kellogg School of Management）的工商管理硕士学位。
Matthew P. Ottmer,Mr. Ottmer has served as our Chief Operating Officer since September 2017. Prior to joining us, Mr. Ottmer served as the Chief Operating Officer of Momenta Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from December 2015 to April 2017. Prior to joining Momenta Pharmaceuticals, Mr. Ottmer served as Senior Vice President, Strategy & Emerging Businesses of Biogen from July 2014 to July 2015. Prior to his appointment as Senior Vice President, Mr. Ottmer held various other positions of increasing responsibility at Biogen from 1999 to July 2015 including serving as Senior Vice President, Strategy and Emerging Business from July 2014 to July 2015 head of the Tysabri business from March 2012 to July 2014 and as Chief of Staff to the Chief Executive Officer from October 2010 to March 2012. Mr. Ottmer received a B.A. in Political Science from the University of Michigan and an M.B.A. from Northwestern University’s Kellogg School of Management.- Matthew P. Ottmer，2015年12月以来，他一直是我们的首席运营官。他曾担任Biogen, Inc.（生物技术公司）的高级副总裁，负责策略和新兴企业（2014年7月至2015年7月）。此前，他曾担任Biogen公司的那他珠单抗（Tysabri）业务负责人（2012年3月至2014年7月），也曾担任Biogen公司的首席执行官的首席职员（2010年10月至2012年3月）。他于1999年加入Biogen公司。他持有the University of Michigan的政治科学学士学位，以及西北大学凯洛格管理学院（Northwestern University's Kellogg School of Management）的工商管理硕士学位。
- Matthew P. Ottmer,Mr. Ottmer has served as our Chief Operating Officer since September 2017. Prior to joining us, Mr. Ottmer served as the Chief Operating Officer of Momenta Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from December 2015 to April 2017. Prior to joining Momenta Pharmaceuticals, Mr. Ottmer served as Senior Vice President, Strategy & Emerging Businesses of Biogen from July 2014 to July 2015. Prior to his appointment as Senior Vice President, Mr. Ottmer held various other positions of increasing responsibility at Biogen from 1999 to July 2015 including serving as Senior Vice President, Strategy and Emerging Business from July 2014 to July 2015 head of the Tysabri business from March 2012 to July 2014 and as Chief of Staff to the Chief Executive Officer from October 2010 to March 2012. Mr. Ottmer received a B.A. in Political Science from the University of Michigan and an M.B.A. from Northwestern University’s Kellogg School of Management.
- Jane Pritchett Henderson
Jane Pritchett Henderson，亨德森女士自2017年1月起担任我们的首席财务官兼高级副总裁，企业发展。在加入我们之前，亨德森女士曾担任Kolltan制药公司的高级副总裁，首席财务官兼商务官，于2013年2月加入这家私人控股的生物制药公司，并于2016年11月领导将Kolltan出售给Celldex Pharmaceuticals，Inc.。此前，2010年6月至2012年6月，Henderson女士担任ISTAPharmaceuticals，Inc.（一家公开上市的制药公司）的业务发展Vice President，当时ISTA Pharmaceuticals被Bausch+Lomb收购。在加入ista Pharmaceuticals之前，亨德森女士曾担任Axerion Therapeutics，Inc.（一家私人持有的生物技术公司）的执行Vice President、首席财务官和业务开发主管，以及Panacos Pharmaceuticals，Inc.（一家公开上市的生物制药公司）的执行Vice President、首席财务官和首席商务官。亨德森女士自2013年10月起担任Eleven Biotherapeutics，Inc.的董事会成员，自2018年1月起担任生物制药公司Ophthotech Corp.的董事会成员。Henderson女士在杜克大学（Duke University）获得心理学学士学位。
Jane Pritchett Henderson has served as our Chief Financial Officer since December 2020. In addition, Ms. Henderson serves as a director and chair of the audit committee of Akero Therapeutics, Inc. since April 2019 of IVERIC bio, Inc. since January 2018 and of Sesen Bio, Inc., formerly Eleven Biotherapeutics, Inc., since October 2013. Prior to joining Adagio, Ms. Henderson served as Chief Financial Officer of Turnstone Biologics from June 2018 to December 2020 Chief Financial Officer and Senior Vice President, Corporate Development of Voyager Therapeutics, Inc. from January 2017 to June 2018 and Senior Vice President and Chief Financial & Business Officer of Kolltan Pharmaceuticals, Inc. from February 2013 to November 2016. Ms. Henderson received a B.S. in Psychology from Duke University.- Jane Pritchett Henderson，亨德森女士自2017年1月起担任我们的首席财务官兼高级副总裁，企业发展。在加入我们之前，亨德森女士曾担任Kolltan制药公司的高级副总裁，首席财务官兼商务官，于2013年2月加入这家私人控股的生物制药公司，并于2016年11月领导将Kolltan出售给Celldex Pharmaceuticals，Inc.。此前，2010年6月至2012年6月，Henderson女士担任ISTAPharmaceuticals，Inc.（一家公开上市的制药公司）的业务发展Vice President，当时ISTA Pharmaceuticals被Bausch+Lomb收购。在加入ista Pharmaceuticals之前，亨德森女士曾担任Axerion Therapeutics，Inc.（一家私人持有的生物技术公司）的执行Vice President、首席财务官和业务开发主管，以及Panacos Pharmaceuticals，Inc.（一家公开上市的生物制药公司）的执行Vice President、首席财务官和首席商务官。亨德森女士自2013年10月起担任Eleven Biotherapeutics，Inc.的董事会成员，自2018年1月起担任生物制药公司Ophthotech Corp.的董事会成员。Henderson女士在杜克大学（Duke University）获得心理学学士学位。
- Jane Pritchett Henderson has served as our Chief Financial Officer since December 2020. In addition, Ms. Henderson serves as a director and chair of the audit committee of Akero Therapeutics, Inc. since April 2019 of IVERIC bio, Inc. since January 2018 and of Sesen Bio, Inc., formerly Eleven Biotherapeutics, Inc., since October 2013. Prior to joining Adagio, Ms. Henderson served as Chief Financial Officer of Turnstone Biologics from June 2018 to December 2020 Chief Financial Officer and Senior Vice President, Corporate Development of Voyager Therapeutics, Inc. from January 2017 to June 2018 and Senior Vice President and Chief Financial & Business Officer of Kolltan Pharmaceuticals, Inc. from February 2013 to November 2016. Ms. Henderson received a B.S. in Psychology from Duke University.
- Jane P. Henderson
JaneP.Henderson自2018年1月以来一直担任我们的董事会成员。亨德森女士自2018年6月起担任Turnstone Biologics（一家私营生物技术公司）的首席财务官。从2017年1月至2018年6月，亨德森女士担任VoyagerTherapeutics，Inc.公司（一家上市的临床阶段基因治疗公司）的首席财务官兼高级副总裁，企业发展。2013年至2016年，亨德森担任私营制药公司Kolltan制药公司的高级副总裁，首席财务官和商务官，2010年至2012年，亨德森担任ISTA Pharmaceuticals，Inc.的业务发展Vice President，ISTA Pharmaceuticals，Inc.是一家上市的专业制药公司，直到被Bausch&Lomb Incorporated收购。此前，亨德森女士曾担任Axerion Therapeutics，Inc.的首席财务官兼业务开发主管，以及Panacos Pharmaceuticals，Inc.的首席财务官兼首席商务官，这两家公司都是私营生物技术公司。除了行业经验外，亨德森女士还在汇丰控股有限公司、Canadian Imperial Bank of Commerce、雷曼兄弟和所罗门兄弟公司担任董事总经理和其他高级职务。亨德森女士目前在Sesen Bio Inc.和AkeroTherapeutics，Inc.的董事会任职，这两家公司都是公开上市的生物技术公司。Henderson女士在杜克大学（Duke University）获得心理学学士学位。
Jane P. Henderson has served as Adagio Therapeutics, Inc. Chief Financial Officer since December 2020. She has served as a member of IVERIC bio, Inc. of directors since January 2018. Ms. Henderson has served as chief financial officer of Turnstone Biologics, a privately-held biotechnology company, since June 2018. From January 2017 to June 2018 Ms. Henderson served as chief financial officer and senior vice president, corporate development at Voyager Therapeutics, Inc., a publicly-traded clinical-stage gene therapy company. From 2013 to 2016 Ms. Henderson served as senior vice president, chief financial and business officer of Kolltan Pharmaceuticals, Inc., which was a privately held pharmaceutical company, and from 2010 to 2012 Ms. Henderson served as vice president, business development of ISTA Pharmaceuticals, Inc, a publicly-traded specialty pharmaceutical company, until its acquisition by Bausch & Lomb Incorporated. Previously, Ms. Henderson served as chief financial officer and head of business development at Axerion Therapeutics, Inc., and chief financial officer and chief business officer of Panacos Pharmaceuticals, Inc, both privately held biotechnology companies. In addition to her industry experience, Ms. Henderson was managing director and held other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson currently serves on the boards of directors of Sesen Bio Inc. and Akero Therapeutics, Inc., both of which are publicly traded biotechnology companies. Ms. Henderson received a B.S. in psychology from Duke University.- JaneP.Henderson自2018年1月以来一直担任我们的董事会成员。亨德森女士自2018年6月起担任Turnstone Biologics（一家私营生物技术公司）的首席财务官。从2017年1月至2018年6月，亨德森女士担任VoyagerTherapeutics，Inc.公司（一家上市的临床阶段基因治疗公司）的首席财务官兼高级副总裁，企业发展。2013年至2016年，亨德森担任私营制药公司Kolltan制药公司的高级副总裁，首席财务官和商务官，2010年至2012年，亨德森担任ISTA Pharmaceuticals，Inc.的业务发展Vice President，ISTA Pharmaceuticals，Inc.是一家上市的专业制药公司，直到被Bausch&Lomb Incorporated收购。此前，亨德森女士曾担任Axerion Therapeutics，Inc.的首席财务官兼业务开发主管，以及Panacos Pharmaceuticals，Inc.的首席财务官兼首席商务官，这两家公司都是私营生物技术公司。除了行业经验外，亨德森女士还在汇丰控股有限公司、Canadian Imperial Bank of Commerce、雷曼兄弟和所罗门兄弟公司担任董事总经理和其他高级职务。亨德森女士目前在Sesen Bio Inc.和AkeroTherapeutics，Inc.的董事会任职，这两家公司都是公开上市的生物技术公司。Henderson女士在杜克大学（Duke University）获得心理学学士学位。
- Jane P. Henderson has served as Adagio Therapeutics, Inc. Chief Financial Officer since December 2020. She has served as a member of IVERIC bio, Inc. of directors since January 2018. Ms. Henderson has served as chief financial officer of Turnstone Biologics, a privately-held biotechnology company, since June 2018. From January 2017 to June 2018 Ms. Henderson served as chief financial officer and senior vice president, corporate development at Voyager Therapeutics, Inc., a publicly-traded clinical-stage gene therapy company. From 2013 to 2016 Ms. Henderson served as senior vice president, chief financial and business officer of Kolltan Pharmaceuticals, Inc., which was a privately held pharmaceutical company, and from 2010 to 2012 Ms. Henderson served as vice president, business development of ISTA Pharmaceuticals, Inc, a publicly-traded specialty pharmaceutical company, until its acquisition by Bausch & Lomb Incorporated. Previously, Ms. Henderson served as chief financial officer and head of business development at Axerion Therapeutics, Inc., and chief financial officer and chief business officer of Panacos Pharmaceuticals, Inc, both privately held biotechnology companies. In addition to her industry experience, Ms. Henderson was managing director and held other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson currently serves on the boards of directors of Sesen Bio Inc. and Akero Therapeutics, Inc., both of which are publicly traded biotechnology companies. Ms. Henderson received a B.S. in psychology from Duke University.
- Steven M. Paul
Steven M. Paul ，目前是阿佩尔阿尔茨海默氏症研究所主任，康奈尔大学威尔医学院神经病学，神经科学，精神病学和药理学教授。他有着超过20年的制药和生物技术行业的管理经验，及37多年的科研经验。他于2010年退休，时任美国礼来公司科学技术部执行副总裁，礼来研究实验室总裁，这是一个从事医药产品的研究，开发，制造销售的公司，他自2003年起担任该职。他于1993年加入礼来，此后在礼来公司的研究机构，担任了愈益重要的职务，其中包括探索研究与临床调查部副总裁。加入礼来之前，他曾在国家心理健康研究所担任多个高级职务，其中包括院内研究项目的科学顾问。他撰写或与他人合写了500余篇论文和特约书刊章节，并担任许多科学期刊的编委，及一些校外和校内委员会的授予校对人。他是Alnylam制药的董事，Third Rock Ventures的投资合伙人。他也是美国国家卫生研究院的董事，国家科学院医学研究所的成员，美国科学发展协会会员。他获得了杜兰大学医学博士，理科硕士和文科学士学位
Steven M. Paul, M.D.,Dr. Paul has served as our President, Chief Executive Officer, and member of the Board of Directors since September 2014. From June 2013 to September 2014 Dr. Paul served as our Interim President of Research and Development. Since September 2010 he has also served as a Venture Partner at Third Rock Ventures, LLC, a life sciences venture capital firm focused on the formation, development and strategy of new companies. Additionally, Dr. Paul has served as a professor or an adjunct professor of neuroscience at Weill Cornell Medical College since August 2010. Prior to that, from 1993 to 2010 Dr. Paul held several key positions at Eli Lilly and Company, a pharmaceutical company, including Executive Vice President, President of Lilly Research Laboratories, Vice President of Neuroscience CNS Research and Group Vice President of Discovery Research. Prior to Eli Lilly, from 1988 to 1993 Dr. Paul served as the Scientific Director of the National Institute of Mental Health. Dr. Paul also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Dr. Paul is an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine. He has also served on the boards of directors of publicly traded biopharmaceutical companies Alnylam Pharmaceuticals, Inc. since August 2010 and Sage Therapeutics, Inc. since September 2011. Dr. Paul has also served as a member of the Advisory Council of the National Institute of General Medical Sciences and was appointed by the Secretary of the Department of Health and Human Services as a member of the advisory committee to the Director of the National Institutes of Health, or NIH, from 2001 to 2005. He is currently the Chairman of the Foundation for the NIH board of directors. Dr. Paul is also board certified by the American Board of Psychiatry and Neurology. Dr. Paul received a B.A. in Biology and Psychology from Tulane University, and an M.S. and M.D. from the Tulane University School of Medicine.- Steven M. Paul ，目前是阿佩尔阿尔茨海默氏症研究所主任，康奈尔大学威尔医学院神经病学，神经科学，精神病学和药理学教授。他有着超过20年的制药和生物技术行业的管理经验，及37多年的科研经验。他于2010年退休，时任美国礼来公司科学技术部执行副总裁，礼来研究实验室总裁，这是一个从事医药产品的研究，开发，制造销售的公司，他自2003年起担任该职。他于1993年加入礼来，此后在礼来公司的研究机构，担任了愈益重要的职务，其中包括探索研究与临床调查部副总裁。加入礼来之前，他曾在国家心理健康研究所担任多个高级职务，其中包括院内研究项目的科学顾问。他撰写或与他人合写了500余篇论文和特约书刊章节，并担任许多科学期刊的编委，及一些校外和校内委员会的授予校对人。他是Alnylam制药的董事，Third Rock Ventures的投资合伙人。他也是美国国家卫生研究院的董事，国家科学院医学研究所的成员，美国科学发展协会会员。他获得了杜兰大学医学博士，理科硕士和文科学士学位
- Steven M. Paul, M.D.,Dr. Paul has served as our President, Chief Executive Officer, and member of the Board of Directors since September 2014. From June 2013 to September 2014 Dr. Paul served as our Interim President of Research and Development. Since September 2010 he has also served as a Venture Partner at Third Rock Ventures, LLC, a life sciences venture capital firm focused on the formation, development and strategy of new companies. Additionally, Dr. Paul has served as a professor or an adjunct professor of neuroscience at Weill Cornell Medical College since August 2010. Prior to that, from 1993 to 2010 Dr. Paul held several key positions at Eli Lilly and Company, a pharmaceutical company, including Executive Vice President, President of Lilly Research Laboratories, Vice President of Neuroscience CNS Research and Group Vice President of Discovery Research. Prior to Eli Lilly, from 1988 to 1993 Dr. Paul served as the Scientific Director of the National Institute of Mental Health. Dr. Paul also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Dr. Paul is an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine. He has also served on the boards of directors of publicly traded biopharmaceutical companies Alnylam Pharmaceuticals, Inc. since August 2010 and Sage Therapeutics, Inc. since September 2011. Dr. Paul has also served as a member of the Advisory Council of the National Institute of General Medical Sciences and was appointed by the Secretary of the Department of Health and Human Services as a member of the advisory committee to the Director of the National Institutes of Health, or NIH, from 2001 to 2005. He is currently the Chairman of the Foundation for the NIH board of directors. Dr. Paul is also board certified by the American Board of Psychiatry and Neurology. Dr. Paul received a B.A. in Biology and Psychology from Tulane University, and an M.S. and M.D. from the Tulane University School of Medicine.